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Hypertrophic cardiomyopathy is a primary myocardial disorder with an autosomal pattern of
inheritance characterized by inappropriate myocardial hypertrophy. Annual mortality has
been reported to be 1% to 2% and sudden death represents the most common cause.
Treatment strategies are 1) medical therapy in patients with mild to moderate symptoms, 2)
reduction of septal hypertrophy by surgical myectomy or alcohol ablation, and 3) implantation
of an automatic cardioverter-defibrillator in the presence of non-sustained ventricular
tachyarrhythmias. A debate has been started on whether surgical myectomy or alcohol
ablation of the septum is the appropriate treatment for hypertrophic obstructive cardiomy-
opathy. Surgical (transaortic) myectomy has been the gold standard in the past 20 to 30 years
for treatment of symptomatic patients with significant hemodynamic outflow tract obstruc-
tion. However, modern interventional technologies allow reduction of the myocardial septum
by injection of alcohol into the first or second septal branch under guidance of two-
dimensional (2D)-contrast echocardiography. This percutaneous technique not only has a
lower morbidity than surgical myectomy but can be guided precisely by 2D echocardiography.
One potential complication is transient (30%) or permanent (10%) atrioventricular block
III; however, this complication is relatively rare. A randomized trial comparing the two
treatment modalities is lacking, and the chance is small that such a trial will be performed
because alcohol ablation can be done with high success and low complication rates, leaving
only complex interventions (with valvular reconstructions and so on) for surgical
myectomy. (J Am Coll Cardiol 2004;44:2054–5) © 2004 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.047Cardiology Foundation
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sypertrophic cardiomyopathy (HCM) is characterized by
symmetric hypertrophy of the septum with or without
ynamic obstruction of the outflow tract (1–3) and in-
reased diastolic filling pressure ( diastolic dysfunction).
ypertrophic cardiomyopathy is a primary myocardial dis-
rder with an autosomal pattern of inheritance. The prev-
lence of HCM in the general population has been esti-
ated as 1:500, higher than was previously postulated.
everal genetic studies have described HCM as a heteroge-
eous disease of the sarcomers that involves more than 150
ifferent mutations in at least 10 different contractile pro-
eins. This genetic complexity leads to a wide diversity in
ardiac morphology, pathophysiologic features, and clinical
anifestations even in a single family (3–5). Annual mor-
ality for HCM in an unselected population has been
eported to be about 1% to 2%, and sudden death represents
he most common cause. Sudden death is assumed to be due
o idiopathic ventricular arrhythmias, but hemodynamic
actors and myocardial ischemia may be involved as well
4,5). Treatment strategies in HCM (Fig. 1) are three-fold:
) medical therapy in patients with mild to moderate
ymptoms, 2) reduction of the myocardial septum by surgery
r alcohol ablation in patients with severe symptoms or
ignificant outflow tract obstruction (6–8), and 3) implan-
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ccepted August 16, 2004.ation of an automatic cardioverter-defibrillator in the
resence of nonsustained ventricular tachyarrhythmias (5).
Surgical myectomy has been the gold standard for symp-
omatic patients with significant hemodynamic outflow
ract obstruction (systolic pressure gradient at rest 50 mm
g, after provocation 100 mm Hg) for more than 20
ears. Long-term follow-up studies after septal myectomy
ave shown excellent results with low morbidity and mor-
ality (6). However, dilation of the left ventricle after
urgical myectomy and the occurrence of aortic regurgita-
ion after transvalvular reduction of the myocardium have
een reported as potential complication of this procedure.
n 1996, Sigwart (7) introduced a new catheter-based
onsurgical reduction therapy of the interventricular septum
y infusion of small amounts of pure alcohol into the first or
econd septal branch of the left anterior decending coronary
rtery. After early skepticism, this percutaneous treatment
trategy has led to a new treatment option without the need
or opening the chest and ascending aorta for removal of the
xcessive myocardium in the left ventricular outflow tract
8). This technique has gained great popularity in the past
ew years and has led to a rapid expansion of this treatment
ainly in European countries (9). Complications associated
ith alcohol ablation of the septum have been rare and in
he range of the surgical myectomy. Transients of perma-
ent atrioventricular block III have been reported to be
omewhat higher than after surgery. However, temporary
acemaker implantation during the procedure has solved the
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November 16, 2004:2054–5 Alcohol Ablation in HOCMroblem of transient block, and permanent pacemaker
mplantations have decreased from 25% to 10% with the
eduction in the amount of injected alcohol (8). The fear of
igher incidence of tachyarrhythmias after ablation has
ever been substantiated.
Most centers with experience in nonsurgical reduction of
he interventricular septum by alcohol injection (9) have
dopted this technique as a first line treatment of patients
ith hypertrophic obstructive cardiomyopathy (HOCM).
he surgical treatment of HOCM has been reserved for
atients with comorbidities such as organic mitral regurgi-
ation or severe coronary artery disease requiring coronary
ypass grafting, although simultaneous treatment of coro-
ary artery disease by percutaneous interventions with stent
mplantation and alcohol ablation of the septum has been
erformed in patients with HCM.
Catheter-based treatment for HOCM has received much
ttention and has become the treatment of choice. Surgery
s an effective treatment strategy but is associated with
onsiderably higher perioperative morbidity. Surgical myec-
omy was the treatment of choice for the past 40 years,
hereas alcohol ablation of the septum is the treatment of
Abbreviations and Acronyms
HCM  hypertrophic cardiomyopathy
HOCM  hypertrophic obstructive cardiomyopathy
igure 1. Treatment strategy in hypertrophic cardiomyopathy (HCM).
CD  implantable cardioverter-defibrillator; NSVT  nonsustained
entricular tachycardia.hoice for patients with HOCM in the 21st century. It is
lear that answering the question whether alcohol ablation
r surgical myectomy is the treatment of choice would
equire a randomized trial comparing these two treatment
odalities in a larger population of 240 patients in each
roup (80% power; event rate 7% in population 1 and 15%
n population 2). It would require many centers worldwide
o obtain this number of patients in a reasonable time span.
owever, for the invasive cardiologist who is doing alcohol
blation, it is clear that the percutaneous approach is much
asier and is successful in many patients who would be hard
o enroll in a randomized trial. Thus, it appears obvious to
s that alcohol ablation is the treatment of choice for the
ew century.
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